
|Videos|November 16, 2022
Real-World Outcomes Data on Lenvatinib as Monotherapy in Patients with RAI-R-DTC
Author(s)Lori J. Wirth, MD
Dr Lori Wirth reviews real-world outcomes data on lenvatinib treatment in patients with RAI-R-DTC and how they compare to the SELECT trial.
Advertisement
Episodes in this series

Now Playing
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5





















